Bridge­Bio rais­es up to $1.2B, a month af­ter sub­mit­ting car­dio drug to FDA

Bridge­Bio has tapped in­vestors for up to $1.25 bil­lion as it pre­pares to com­mer­cial­ize its heart pill and get some breath­ing room to con­tin­ue run­ning mul­ti­ple clin­i­cal tri­als across car­diore­nal, on­col­o­gy and oth­er dis­ease ar­eas.

The fi­nanc­ing haul ar­rives a month af­ter Bridge­Bio sub­mit­ted aco­ramidis for FDA ap­proval and near­ly four months af­ter it inked a $250 mil­lion pri­vate place­ment.

An­a­lysts and in­dus­try in­sid­ers have been wait­ing to see what kind of trans­ac­tion the Pa­lo Al­to biotech would make af­ter it an­nounced its Phase III car­dio drug suc­cess last year, which came af­ter a long odyssey for the com­pa­ny and end­ed up be­ing one of the in­dus­try’s stand­out mo­ments in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER